Hansa Biopharma AB (publ) (LON:0RC7)

London flag London · Delayed Price · Currency is GBP · Price in SEK
26.28
+0.34 (1.31%)
At close: Jun 11, 2025
Market Cap 136.39M
Revenue (ttm) 14.01M
Net Income (ttm) -48.25M
Shares Out n/a
EPS (ttm) -0.72
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,370
Average Volume 2,303
Open 26.31
Previous Close 25.94
Day's Range 25.66 - 26.28
52-Week Range 20.10 - 57.30
Beta 1.53
RSI 59.86
Earnings Date Jul 17, 2025

About Hansa Biopharma AB

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoi... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2007
Employees 135
Stock Exchange London Stock Exchange
Ticker Symbol 0RC7
Full Company Profile

Financial Performance

In 2024, Hansa Biopharma AB's revenue was 171.32 million, an increase of 27.76% compared to the previous year's 134.09 million. Losses were -807.24 million, -2.94% less than in 2023.

Financial numbers in SEK Financial Statements

News

There is no news available yet.